EUR 0.13
(-0.94%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 53.9 Million EUR | 1.79% |
2022 | 52.95 Million EUR | 13.44% |
2021 | 46.68 Million EUR | 22.21% |
2020 | 38.19 Million EUR | 15.19% |
2019 | 33.16 Million EUR | -33.33% |
2018 | 49.73 Million EUR | 4.87% |
2017 | 47.42 Million EUR | 334.37% |
2016 | 10.91 Million EUR | 23.79% |
2015 | 8.82 Million EUR | -46.13% |
2014 | 16.37 Million EUR | -49.27% |
2013 | 32.27 Million EUR | 310.22% |
2012 | 7.86 Million EUR | 178.3% |
2011 | 2.82 Million EUR | 33.66% |
2010 | 2.11 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q2 | 54.69 Million EUR | 0.0% |
2023 FY | - EUR | -100.0% |
2023 Q4 | 53.9 Million EUR | 0.0% |
2022 Q2 | 42.61 Million EUR | 0.0% |
2022 Q4 | 52.95 Million EUR | 0.0% |
2022 FY | 52.95 Million EUR | 13.44% |
2021 FY | 46.68 Million EUR | 22.21% |
2021 Q4 | 46.68 Million EUR | 0.0% |
2021 Q2 | 53.75 Million EUR | 0.0% |
2020 Q4 | 38.19 Million EUR | 0.0% |
2020 FY | 38.19 Million EUR | 15.19% |
2020 Q2 | 29.85 Million EUR | 0.0% |
2019 Q2 | 40.26 Million EUR | 0.0% |
2019 Q4 | 33.16 Million EUR | 0.0% |
2019 FY | 33.16 Million EUR | -33.33% |
2018 Q2 | 72.9 Million EUR | 0.0% |
2018 FY | 49.73 Million EUR | 4.87% |
2018 Q4 | 49.73 Million EUR | 0.0% |
2017 Q2 | 7.33 Million EUR | 0.0% |
2017 FY | 47.42 Million EUR | 334.37% |
2017 Q4 | 47.42 Million EUR | 0.0% |
2016 Q2 | 11.07 Million EUR | 0.0% |
2016 FY | 10.91 Million EUR | 23.79% |
2016 Q4 | 10.91 Million EUR | 0.0% |
2015 FY | 8.82 Million EUR | -46.13% |
2015 Q2 | 7.58 Million EUR | 0.0% |
2015 Q4 | 8.82 Million EUR | 0.0% |
2014 Q2 | 33.97 Million EUR | 0.0% |
2014 Q4 | 16.37 Million EUR | 0.0% |
2014 FY | 16.37 Million EUR | -49.27% |
2013 Q4 | 32.27 Million EUR | 0.0% |
2013 FY | 32.27 Million EUR | 310.22% |
2012 FY | 7.86 Million EUR | 178.3% |
2011 FY | 2.82 Million EUR | 33.66% |
2010 FY | 2.11 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -679.818% |
ABIVAX Société Anonyme | 131.05 Million EUR | 58.871% |
Adocia SA | 31.87 Million EUR | -69.128% |
Aelis Farma SA | 13.08 Million EUR | -312.087% |
Biophytis S.A. | 15.84 Million EUR | -240.091% |
Advicenne S.A. | 24.37 Million EUR | -121.114% |
genOway Société anonyme | 14.45 Million EUR | -272.772% |
IntegraGen SA | 5.97 Million EUR | -801.385% |
Medesis Pharma S.A. | 6.42 Million EUR | -738.772% |
Neovacs S.A. | 3.71 Million EUR | -1352.026% |
NFL Biosciences SA | 3.62 Million EUR | -1388.697% |
Plant Advanced Technologies SA | 6.78 Million EUR | -694.724% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -1528.376% |
Sensorion SA | 13.22 Million EUR | -307.499% |
Theranexus Société Anonyme | 5.01 Million EUR | -974.541% |
TME Pharma N.V. | 2.78 Million EUR | -1835.404% |
Valbiotis SA | 13.7 Million EUR | -293.208% |
TheraVet SA | 1.48 Million EUR | -3529.714% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | -163.343% |
argenx SE | 402.79 Million EUR | 86.618% |
BioSenic S.A. | 32.26 Million EUR | -67.062% |
Celyad Oncology SA | 9.97 Million EUR | -440.198% |
DBV Technologies S.A. | 38.74 Million USD | -39.116% |
Galapagos NV | 1.56 Billion EUR | 96.549% |
Genfit S.A. | 105.92 Million EUR | 49.112% |
GeNeuro SA | 20.13 Million EUR | -167.633% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -525.882% |
Innate Pharma S.A. | 132.29 Million EUR | 59.256% |
Inventiva S.A. | 101.59 Million EUR | 46.944% |
MaaT Pharma SA | 22.46 Million EUR | -139.933% |
MedinCell S.A. | 77.77 Million EUR | 30.692% |
Nanobiotix S.A. | 95.74 Million EUR | 43.701% |
Onward Medical N.V. | 25.69 Million EUR | -109.748% |
Oryzon Genomics S.A. | 25.12 Million EUR | -114.527% |
OSE Immunotherapeutics SA | 59.07 Million EUR | 8.765% |
Oxurion NV | 19.73 Million EUR | -173.11% |
Pharming Group N.V. | 228.28 Million EUR | 76.389% |
GenSight Biologics S.A. | 34.72 Million EUR | -55.214% |
Transgene SA | 26.51 Million EUR | -103.27% |
Financière de Tubize SA | 123.65 Million EUR | 56.408% |
UCB SA | 6.56 Billion EUR | 99.179% |
Valneva SE | 341.14 Million EUR | 84.2% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -1085.419% |